share_log

HSBC Initiates Coverage On Actinium Pharma With Buy Rating, Announces Price Target of $11.6

Benzinga ·  Sep 6, 2023 05:06

HSBC analyst Morten Herholdt initiates coverage on Actinium Pharma (AMEX:ATNM) with a Buy rating and announces Price Target of $11.6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment